According to the World Health Organization, untreated surgical conditions, including hernia, contribute notably to the global disease burden. Data from the National Center for Biotechnology Information indicates that inguinal hernia affects nearly 27% of men and around 3% of women during their lifetime. The Ministry of Health and Family Welfare also highlights the importance of early diagnosis and timely surgical care to prevent complications.

Hernia often begins as a small, painless bulge in the groin, abdomen, or near a previous surgical site, leading many individuals to ignore it. However, early signs may include a dragging sensation, mild discomfort, pressure after prolonged standing, and abdominal heaviness or bloating. Recognizing these symptoms early and seeking medical advice is crucial.

Diagnosis is typically straightforward through physical examination, with imaging used in select cases. Early detection allows for simpler and more effective treatment.

“In my practice, I have treated many patients who initially noticed only a small swelling. It is important to understand how this condition can progress if left untreated. With timely intervention, patients are often reassured by how straightforward the procedure is and how quickly symptoms such as swelling and discomfort improve after repair,” said Dr Parmeshwar Bhambrule, Senior Consultant, Healing Hands Hospital.

Advancements in hernia therapy have made treatment safer and more efficient. Minimally invasive techniques involve smaller incisions, resulting in less pain, a quicker recovery, and a shorter hospital stay. The use of surgical mesh to further strengthen the affected area further reduces the risk of recurrence, enabling patients to resume daily activities comfortably.

Delaying treatment can lead to complications such as incarceration, where tissue becomes trapped, or strangulation, a serious condition requiring emergency care.

“I always advise my patients that hernia treatment is not just about correcting a visible bulge but also about preventing complications and improving overall quality of life. Many patients experience better mobility, improved sleep, and a quicker return to normal routines following timely treatment,” said Dr Vinayak Kshirsagar, DY Patil Hospital, Pune.

Maintaining a healthy weight, avoiding excessive strain, and addressing a persistent cough can help reduce risk. Increased awareness, early diagnosis, and timely intervention remain key to effective hernia management and long-term well-being.

The post Early Detection and Timely Treatment in Managing Hernias appeared first on NRI News.

PUNE: Starting a new era in skin treatment, city-based Parimal and Pramod Chaudhari Foundation and the members of the Chaudhari family have donated the all-new state-of-the-art medical equipment for the diagnosis, treatment, and research of skin diseases to the Deenanath Mangeshkar Hospital and Research Centre recently.

With this new equipment, the Dermatology department at the Deenanath Mangeshkar Hospital (DMH) will now be able to offer advanced treatment for skin conditions such as burns, tattoos, dark spots, acne, melasma, and other skin diseases using new modern treatment techniques.

The laser services for the Dermatology Department and Research Center were commenced in the memory of Madhubhau Chaudhary, and state-of-the-art equipment for skull base neurosurgery was dedicated in the memory of Shakutai Madhukar Chaudhari, the parents of noted industrialist Dr. Pramod Chaudhari and the trustee of Parimal and Pramod Chaudhari Foundation.

Dignitaries like Dr. Pramod Chaudhari, Parimal Chaudhari, Sunanda Nisal, Dr. Usha Katti, Dr. Pradyumna Vaidya, Dr. Dhanshree Bhide, Dr. Vinay Kulkarni from the Dermatology Department, neurosurgeon Dr. Kaustubh Dindorkar from the Neurology Department, and renowned surgeon Dr. Utkrant Kurlekar were present during the program that was organized at DMH to mark the installation of the above equipment.

Speaking at the event, Dr. Pramod Chaudhari said, “The dermatology department seems somewhat neglected. Dr. Vinay Kulkarni, a specialist in this department, drew my attention to it. There is a need for more focus here, and there is good scope for research. I was attracted by the word ‘research’ because, in my opinion, research is essential everywhere.”

Parimal Chaudhari said, “Deciding about the department for donating the equipment was a tough process. But then we decided to choose the department of dermatology, which is not in the limelight much.”

Sunanda Nisal said, “The Chaudhari family has a tradition of national service and participation in the freedom struggle. The values of supporting institutions and individuals who do excellent work in the fields of nation-building, society, and education have been passed down to the next generation from their mother, a teacher, and their father, a freedom fighter. The medical equipment donated to the hospital is a part of these values.” Dr. Usha Katti also shared her thoughts.”

On behalf of the DMH, Dr. Pradyumna Vaidya, Dr. Vinay Kulkarni, and Dr. Dhanshree Bhide from the Dermatology Department, and neurosurgeon Dr. Kaustubh Dindorkar from the Neurology Department, provided a detailed technical explanation of the medical equipment. Sanika Joshi presented the vote of thanks.

The post Discover the New Chapter of Skin Treatment at DMH appeared first on NRI News.

The facility was inaugurated by the leadership of Ruby Hall Clinic, including Dr. P.K. Grant, Dr. Simon Grant, and Dr. Himesh Gandhi, alongside the Kalyani family, represented by Dr. Baba Kalyani, Mrs. Sunita Kalyani, and Mr. Amit Kalyani of Bharat Forge. They were joined by international experts from Focal One, including Prof. Pascal (University of Toulouse), Dr. Damian, Vice President and CEO, and Mr. Ryan. The initiative has been made possible by the support of the Kalyani family, who have contributed to establishing the Kalyani Institute of Robotic HIFU Therapy at Ruby Hall Clinic, to improve access to advanced cancer care in India.

With over 40,000 new cases of prostate cancer diagnosed annually in India, many men traditionally delay treatment due to the risks associated with invasive surgery or radiation – specifically concerns regarding recovery time and long-term functional health.
Robotic HIFU addresses these fears by offering:
• Targeted Precision: Destroys cancerous tissue while sparing surrounding healthy structures.
• Non-Invasive Nature: A completely incision-free and radiation-free procedure.
• Rapid Recovery: Typically performed as a day-case, allowing patients to return to their lives almost immediately.
• Preserved Quality of Life: Significantly reduces the risk of urinary and sexual dysfunction compared to traditional methods.

Speaking at the launch, Dr. P.K. Grant, Chairman and Managing Trustee of Ruby Hall Clinic, said, “The introduction of the Indian subcontinent’s first Robotic HIFU therapy at Ruby Hall Clinic marks an important milestone for cancer care in our region. Our commitment has always been to bring advanced and meaningful medical technology to patients in India rather than wait for it to reach us years later. Establishing this programme reflects that philosophy and ensures that our patients have access to treatment options that prioritise both outcomes and quality of life.”

Dr Baba Kalyani, Chairman and Managing Director Bharat Forge, whose family’s philanthropic support made the institute possible, emphasised the importance of local access: “I have always believed that advances in technology should be used for the good of society. This programme is a clear example of how digital and AI-enabled innovation can make a real difference to patients by offering precise, minimally invasive treatment. Under the leadership of Dr Himesh Gandhi, the Robotic HIFU system has already begun delivering encouraging results for patients. I would like to congratulate Dr Purvez Grant and his team for making it possible for us to bring this technology to society.”

Dr Simon Grant, Physician and Trustee, Ruby Hall Clinic, noted, “FOCAL ONE offers a level of precision that allows us to treat only the areas affected by cancer with the intention of maintaining functional outcomes. We assess that cancer control can be achieved while preserving day-to-day quality of life for patients.”

Ms. Natalie Grant Nanda Ruby Hall Clinic, SPL, “Bringing the Indian subcontinent’s first Robotic HIFU therapy to Pune continues that legacy while setting the foundation for the next generation of cancer care. We are honoured to have the support of the Kalyani family in making this possible.”

From a clinical perspective Dr Himesh Gandhi, Consultant Uro-oncologist and Director of Robotic Surgery at Ruby Hall Clinic, said, “For many men, the fear of the treatment is as great as the fear of the cancer itself. Robotic HIFU removes that barrier, offering a non-invasive pathway that prioritises the patient’s functional independence and quick return to daily life.”

With the establishment of the Kalyani Institute of Robotic HIFU Therapy, Ruby Hall Clinic strengthens its position as a leader in advanced oncological care with an emphasis on accessibility, clinical excellence, and improved patient experience.

The post Ruby Hall Clinic in Pune Launches Groundbreaking Robotic HIFU Therapy for Enhanced Patient Care appeared first on NRI News.

HYDERABAD: CARE Hospitals, Banjara Hills, widely recognized as a pioneer in advanced cardiac care in India, has successfully performed an Atrial Fibrillation (AF) Ablation using the newly launched Q Dot technology, placing the hospital among the first centres in India to adopt this next-generation electrophysiology platform.

The procedure was performed on a 57-year-old woman diagnosed with persistent atrial fibrillation and biatrial cardiomyopathy, and she is currently stable and maintaining normal sinus rhythm following the intervention under the care of Dr. M. Srinivasa Rao, Regional Clinical Director & Sr. Interventional Cardiologist, CARE Hospitals, Banjara Hills.

Q Dot is the latest advancement in catheter ablation technology, designed to deliver high-power, short-duration energy with enhanced temperature control and precision. This allows electrophysiologists to complete complex AF procedures in a shorter duration while improving safety and reducing the risks associated with prolonged exposure to anesthesia and radiation.

Speaking about the achievement, Dr. Ramakrishna SVK, Clinical Director – Cardiac Electrophysiology at CARE Hospitals, Banjara Hills, said that the arrival of Q Dot represents a significant development in the treatment of atrial fibrillation in India. He stated that the technology brings a higher degree of accuracy and consistency to ablation therapy, particularly for patients living with long-standing arrhythmias who require advanced intervention beyond medical therapy.

Commenting on the milestone, Biju Nair, Zonal Chief Operating Officer, CARE Hospitals, said that the successful procedure reflects the strength of the hospital’s cardiac program and the depth of its sub-specialty teams. He added that CARE Banjara has been at the forefront of introducing new-generation technologies in cardiac care and will continue to expand access to advanced treatment for patients across the country.

Atrial fibrillation affects nearly 1% of India’s population, with prevalence increasing among people over 40. This development is expected to benefit individuals suffering from symptomatic or persistent atrial fibrillation who have not responded adequately to medication or who are at risk of long-term complications such as heart failure, stroke, and reduced quality of life. It also supports cardiologists, internists, and referring physicians who are seeking reliable clinical partners for electrophysiology evaluation, second-opinion consultations, or interventional management of rhythm disorders. Patients and families seeking clarity on treatment suitability may reach out to the Cardiac Electrophysiology team at CARE Banjara for clinical assessment and counselling.

The successful introduction of Q Dot further strengthens CARE Hospitals, Banjara Hills as a leading centre for advanced cardiac electrophysiology in India and reinforces the organisation’s commitment to combining medical expertise with future-ready technology to improve outcomes for patients with complex cardiac conditions.

The post CARE Hospitals in Banjara Hills Introduces Q Dot Technology for Advanced Treatment of Heart Rhythm Disorders appeared first on NRI News.

The first patient, a 46-year-old man, came to the hospital with a dry, persistent cough, intermittent fever, and weight loss. A chest scan showed left lower lobe pneumonia, which led doctors to assume tuberculosis over cancer. Bronchoscopy with BAL (bronchoalveolar lavage) found the presence of Aspergillus flavus, a lesser-known fungus species. The patient has now recovered completely.

The second instance involved a 56-year-old female who presented with a right upper lobe mass lesion and a thick-walled cavity, both of which were highly suspected of being malignant. In this case, a BAL fungal culture revealed Aspergillus niger. She was successfully treated, and the lesions in her lung gradually disappeared.

Speaking about the case, Dr. Nagesh Dhadge, HOD & Consultant – Respiratory Medicine, Manipal Hospital, Baner, said, “Pulmonary aspergillosis is no longer confined to the immunocompromised. Climate change, air pollution, and excessive moisture during the monsoon season all contribute to non-immunocompromised conditions linked with fungal infections, independent of immune competence. In both cases mentioned, bronchoscopy and antifungal medication led to timely intervention, preventing major consequences. We were able to make a diagnosis after eliminating tuberculosis and malignancy. Bronchoscopy and BAL cultures were important in isolating the fungus species and implementing appropriate care.”

Anand Mote, Cluster Director, Manipal Hospital, Baner, Pune, said, “At Manipal Hospitals, we are committed to treating patients quickly and competently, especially in uncommon and difficult situations. Although rare, these situations serve as strong reflections of the importance of rapid diagnosis and the use of multidisciplinary teams to manage complex infections.”

It is important to urge the public to be alert to persistent respiratory symptoms, particularly during the monsoon season, and to make prompt diagnosis and treatment decisions. Some respiratory symptoms, such as coughing without explanation, fever, and weight loss, should not be taken seriously, especially if a person resides in an environment where fungi can grow rapidly.

The post The Treatment of Rare Pulmonary Aspergillosis in Non-Immunocompromised Patients at Manipal Hospital, Baner appeared first on NRI News.

It’s a significant accomplishment for a woman to finish her breast cancer therapy. However, as oncologists frequently emphasise, surviving is only the first step. The ensuing years may present a unique set of difficulties, some anticipated and some unexpected.

The heart is one of the less well-known issues.

Heart health can be impacted by several cancer treatments, including targeted medicines like trastuzumab, chemotherapy medications like anthracyclines, and chest radiation. Even years after the conclusion of treatment, the effects might not be felt right away; they might develop gradually. Cardio-oncology, a relatively new area of medicine, is significantly improving this situation.

Our goal at Shivamogga’s Sahyadri Narayana Hospital is to always be one step ahead. We have a Breast Cancer Survivorship Clinic every third Thursday of the month, where women who have finished treatment can come for ongoing support. The clinic’s goal is to help survivors live better, not simply longer, by offering everything from lifestyle counselling and advice to heart exams and other follow-up care. A key component of this journey is the cardio-oncology care we provide, which is directed by consultant cardiologist Dr. Sreevatsa Nadig.

One of the most prestigious conferences in the industry, the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, gave us the chance to present our results to a worldwide audience earlier this year.

Our study asked a simple but important question: Are breast cancer survivors more prone to early signs of heart disease?

To investigate this, we examined two cohorts of women: one with a history of breast cancer and another with no such history. We employed a scan known as coronary artery calcium (CAC) scoring, which aids in identifying early heart artery calcification. It’s a non-intrusive method of identifying hidden dangers before they become significant issues.

We were pleasantly surprised by what we discovered!

The two groups did not differ significantly from one another. Breast cancer survivors did not seem to be more susceptible to early heart disease than their peers when receiving the right care and monitoring.

This offers a message of hope—and a practical reminder to us all.

What can GPs and primary care doctors take away from this?

• Follow-up is effective. Long-term issues can be avoided with the use of structured survivorship care.
• Consider more than recurrence. It’s possible that symptoms like fatigue or dyspnoea don’t indicate that the cancer has returned. Heart health should also be taken into account.
• Lives can be saved by early screenings. While not necessary for everyone, CAC scoring can be a helpful tool when used appropriately.
• Collaboration is important. Collaboration between oncologists, cardiologists, general practitioners, and mental health specialists is beneficial to survivors.

For every woman who walks out of the oncology ward cancer-free, the hope is that she steps into a life full of vitality, confidence, and support. That’s why we believe survivorship needs just as much attention as the treatment itself. If you’re caring for a breast cancer survivor, do consider referring them to our clinic. Together, we can make sure their post-cancer journey is not only longer—but healthier and happier too

The post Understanding the Impact of Breast Cancer Treatment on Heart Health appeared first on NRI News.

VISAKHAPATNAM: ICICI Bank, in collaboration with Tata Memorial Centre (TMC), today announced the commencement of the construction of a new building at the Homi Bhabha Cancer Hospital and Research Centre (HBCHRC) in Visakhapatnam, Andhra Pradesh.

With a commitment of over ₹550 crore, the Bank is funding the construction of a state-of-the-art facility spanning nearly 3.9 lakh square feet, equipped with cutting-edge medical technology.

Once operational, the eight-storied new building– ICICI Foundation Block for Child and Blood Cancer—will serve 3,000 patients annually. Currently, HBCHRC, Visakhapatnam, has a capacity of handling 6,200 patients annually.

Designed as one of the largest specialised cancer facilities in eastern India, the new building will house over 215 beds. It is expected to be completed by 2027, subject to necessary approvals. ICICI Foundation for Inclusive Growth, the CSR arm of ICICI Bank, will oversee its implementation.

The foundation stone was unveiled by Pradeep Kumar Sinha, Chairman, ICICI Bank, in the presence of Sandeep Batra, Executive Director, ICICI Bank, and Dr. Sudeep Gupta, Director, Tata Memorial Centre, Mumbai.

Sinha also inaugurated the N.K. Rao Auditorium in the presence of other dignitaries. ICICI Foundation has supported TMC with infrastructure and equipment for the new auditorium.

Pradeep Kumar Sinha, Chairman, ICICI Bank, said, “We are honoured to partner with TMC in a mission towards cancer care that aligns with our philosophy of strengthening critical healthcare infrastructure in the country. This project reflects our commitment to enabling accessible and high-quality medical care for individuals in need. This project, one of the largest in the eastern corridor for child and blood cancer, will serve patients from Andhra Pradesh and nearby eastern states, helping address the growing need for cancer treatment.”

On the occasion, Sandeep Batra, Executive Director, ICICI Bank, stated, “At ICICI Bank, healthcare remains a focus of our CSR initiatives. Two years ago, we announced our partnership with TMC, an institution that has made a profound impact on cancer care in India, by committing ₹1,200 crore to set up three new blocks at TMC’s centres in Visakhapatnam, Navi Mumbai, and New Chandigarh. Recognising TMC’s latest requirements, we are pleased to enhance our commitment to ₹1,800 crore. Spanning a total area of 10.7 lakh square feet, these new blocks are designed to be equipped with state-of-the-art medical facilities and research wings. These blocks will together accommodate 19 LINACs* and 555 beds. Once fully operational, they will serve as regional hubs.”

Dr. Umesh Mahantshetty, Director, Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, said, “We are grateful to ICICI Foundation for their generous donation, which will significantly contribute to the advancement of cancer treatment and research in Pediatric and Hematolymphoid Cancers in this region. The partnership with ICICI Foundation is a testament to the collective efforts of our institutions in providing top-notch care and improving cancer outcomes for patients across the country.”

Dr. Girish Chinnaswamy, Professor & Head, Paediatric Oncology, Tata Memorial Hospital, Mumbai said, “Paediatric & Hematolymphoid Cancers require specialised care in terms of diagnosis, evaluation, treatment, support services including blood centre, nutrition, rehabilitation, etc., and expertise. At HBCHRC Visakhapatnam currently, we have been registering approximately 200 new Paediatric cancer and 350-400 haematolymphoid cancer patients every year in the past 3 years. With the new block added, we will be able to augment the existing services substantially, including expansion of the bone marrow transplant program, and also initiate immunotherapy. This will also provide ample opportunities to undertake research related to patients in this region.”

ICICI Bank’s commitment of ₹550 crore for the Visakhapatnam hospital is a part of the expanded contribution of ₹1,800 crore.

The ICICI Foundation Child and Blood Cancer Block at Visakhapatnam will offer comprehensive treatment options, including:

• Intensive chemotherapy, bone marrow transplantation, and advanced radiation therapy
• Cutting-edge immunotherapies like CAR-T cell therapy
• High-end medical imaging and diagnostics, including three LINAC*, MRI, and CVT-PET scans
• 14 BMT (Bone Marrow Transplant) Rooms, 14 ICUs, 5 Operating theatres
• There will be research laboratories and joint discussion facilities for treatment planning and training

*Linear Accelerators (LINACs) target radiation at the cancer cells with accuracy, sparing the adjoining healthy tissues.

The post Foundation Stone Laid for State-of-the-Art Cancer Care Facility in Visakhapatnam by ICICI Bank and Tata Memorial Centre appeared first on NRI News.

GENEVA: Serum Institute of India (SII) Pvt. Ltd., part of Cyrus Poonawalla Group, the world’s largest vaccine manufacturer, and the not-for-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) signed a memorandum of understanding (MOU) to accelerate the clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs).

Through this collaboration, both SII and DNDi will develop a work plan to implement R&D, additional Phase III clinical trials, and access activities, along with a joint strategy to raise necessary funds and resources. Additionally, a joint project team will be formed to advance clinical trials, to register and deploy the dengue monoclonal antibody in India and other dengue-endemic countries, provided the studies confirm its safety and efficacy.

‘Dengue is a rapidly spreading, climate-sensitive disease for which medicines are urgently needed,’ said Dr André Siqueira, Head of Dengue at DNDi said “We are proud to partner with Serum Institute of India to advance the development of an affordable monoclonal antibody treatment. This partnership brings together complementary strengths to ensure that people most at risk have timely and equitable access to life-saving treatment.’

“India reports tens of thousands of dengue cases every year, with outbreaks occurring every two to three years in different states,” said Dr Kavita Singh, Asia Continental Lead & Director South Asia, DNDi. “What is deeply concerning is that dengue is no longer confined to historically endemic regions but is rapidly expanding into newer states. Addressing this growing threat demands a multi-pronged approach, including strengthened vector control, surveillance, community awareness, and, critically, the development of effective treatments and diagnostics. DNDi’s partnership with Serum Institute of India is a significant step forward in this direction.”

“This collaboration with DNDi will be instrumental in advancing clinical development of a dengue monoclonal antibody in Brazil and potentially other endemic countries in Southeast Asia, with a focus on making treatment affordable and accessible,” said Dr Prasad Kulkarni, Executive Director, Serum Institute of India. “We look forward to the positive impact this effort will have in reducing the burden of dengue and saving lives in vulnerable communities.”

SII has already conducted pre-clinical studies and Phase I and II clinical trials that show the candidate (formerly VIS513) is safe and effective. Currently, SII is leading the pivotal Phase III clinical trial in India for licensure.

SII and DNDi will now work together to conduct additional Phase III trials in other dengue-endemic countries, including Brazil.

DNDi will act as the lead partner for these Phase III clinical trials, including trial leadership, sponsorship, and implementation in Brazil and potentially other endemic countries in Southeast Asia. DNDi and SII will lead strategic engagement efforts with the Dengue Alliance, relevant industry stakeholders, and policymakers in low- and middle-income countries.

For the DNDi-led trial in Brazil and other countries, SII will provide development background and technical support. Furthermore, SII will be responsible for the manufacture, development, and provision of clinical supplies of the monoclonal antibody candidate. The company will define and execute the regulatory strategy in India and will lead the commercialization of the product in the country.

Launched in 2022, the Dengue Alliance is a global partnership led by institutions from dengue-endemic countries and DNDi that aims to develop affordable and accessible treatments for dengue. The organization will also contribute to the regulatory and commercialization strategy in LMICs and will lead policy and advocacy activities to advance equitable access.

Dengue poses a significant threat, with 3.9 billion people at risk and cases more than doubling each year since 2021. It is also spreading to non-endemic areas due to climate change and urbanization. Despite its prevalence and severity, there is still no specific treatment available for dengue. Medicines that could prevent mild cases from becoming severe would therefore play an important role in reducing mortality and preventing hospitals from being overwhelmed during outbreaks.

The post Serum Institute of India and DNDi Unite to Tackle Dengue in Low- and Middle-Income Nations appeared first on NRI News.

MUMBAI: With the onset of monsoon in different parts of the country, snakebites, particularly in rural areas, are on the rise. Ahead of this, Bharat Serums and Vaccines Limited (BSV), a Mankind Group Company and a leader in high-quality snake antivenom for over two decades, has lined up focused initiatives that will ensure access and availability of the appropriate treatment, while driving awareness on snakebite management and dispelling the myths around it. 

Sivani Sarma Deka, COO-India Business, said, “As a market leader in anti-snake venom, BSV has been at the forefront of developing and bringing quality and effective treatments for snakebites.  We believe it is our responsibility to ensure that we address the 4A’s-Awareness, Access, Availability, and Action- such that the right treatment is administered at the right time and at the right place to the right patient. For this, we continue to forge multi-sectoral collaboration and targeted interventions through awareness and community education on prevention, first aid, early access of snakebite patients to the nearest health facility, and managing snakebite, in the appropriate manner, to dispel the age-old myths of snake bite and its treatment.  In addition, we are also actively focused on continuous medical education with scientific programs curated for healthcare providers that comprise continuous updating of knowledge and practices during management of Snakebite Envenomation (SBE), through the implementation of the prescribed Standard Treatment Guidelines (STG) of the Government.”  

Speaking on awareness, Dr. Sadanand Raut, Shivneri Bhushan, Arogya Ratna Govt. of Maharashtra 2023 MD (Gen. Med.) Consultant Physician, Cardiologist, Diabetologist, and Toxicologist added, “The Central Government’s move on making snakebites a ‘notifiable disease’ will help in improving data collection, resource allocation, prevention, and access to early treatment,t leading to track incidence, early identification, and interventions to prevent further mortality/morbidity.  In addition, it will play a significant role in creating a registry of suspected or probable cases and deaths due to snakebite, thereby ensuring improved surveillance, data collection, and ultimately reducing snakebite deaths and disabilities.  This will bring the much-needed focus on   addressing gaps in the availability of snake antivenom and medical care, and most importantly, fostering community engagement by encouraging local participation in prevention efforts.”

Dr. Sadanand Raut, Shivneri Bhushan, Arogya Ratna Govt. of Maharashtra 2023 MD(Gen. Med.) Consultant Physician, Cardiologist, Diabetologist, and Toxicologist highlighted, “Annually, over 58,000 reported deaths occur in India due to snakebites. The incidence of high mortality and morbidity prevails.  Improving snakebite outcomes involves a multi-pronged approach from identification to early access to treatment, as it is crucial for managing the complications of envenoming and improving patient outcomes. We can save the lives of snakebite victims by enhancing understanding, building awareness, and educating communities on snakebites as well as ensuring wider access and availability of treatments across the country.”

Snakebite remains a serious public health challenge.  There is a need to create a holistic strategy to address the socioeconomic challenges of snakebites, the availability of snake antivenom and medical care, and most importantly, increase awareness and levels of community engagement by encouraging local participation in prevention efforts.

The post The Urgent Need for Snakebite Awareness appeared first on NRI News.

NEW DELHI: PRIVÉ LUXE Skin and Wellness Clinic, the luxury wellness space founded by celebrated dermatologists and cosmetologist Dr. Amit Bhasin and Dr. Aarti Bhasin, has announced the grand opening of its second clinic at Vasant Vihar, Delhi. The new space marks a bold evolution in the clinic’s vision, offering not just skincare but a transformative, holistic approach to health and beauty rooted in science, empathy, and results.

The new clinic introduces India’s first authentic Korean PDRN + Exosome therapy, a regenerative treatment that is rapidly gaining popularity across Asia for its ability to heal damaged skin, improve texture, and deeply hydrate at a cellular level. PDRN (Polydeoxyribonucleotide), derived from salmon DNA, is renowned for its skin-repairing and rejuvenating properties. Combined with Exosomes—nano-sized messengers rich in growth factors and peptides—this treatment provides extraordinary results in skin regeneration, collagen stimulation, pigmentation reduction, and anti-ageing.

“At PRIVÉ luxe, we believe true luxury lies in feeling your best—inside and out,” says Dr. Amit Bhasin, Managing Director of PRIVÉ Luxe and a leading voice in Indian dermatology. “PDRN + Exosomes represent a breakthrough in skin healing, and we are proud to be the first in India to introduce the authentic Korean formulation. My expertise has always focused on achieving results that enhance one’s natural features—subtle, refined, and true to everyone’s unique beauty.”

Dr. Aarti Bhasin, CEO, PRIVÉ Luxe, added, “What makes PRIVÉ special is the way we combine precision with empathy. We don’t believe in one-size-fits-all treatments. Every individual’s skin tells a story, and our role is to listen carefully before deciding how best to support it. PDRN fits beautifully into this philosophy — it is gentle, effective, and works in harmony with the skin rather than overpowering it. We are proud to be the first to introduce it in India, the way it is meant to be experienced.”

Privé Skin Clinic goes beyond conventional dermatological services by embracing a philosophy rooted in holistic wellness. Rooted in the belief that external radiance stems from internal balance, the clinic’s Skin & Wellness philosophy combines advanced dermatological treatments with clinical dietetics, physiotherapy, psychology, Ayurveda, internal medicine, and even aesthetic plastic surgery. Each patient’s journey is mapped with intention, addressing not just visible symptoms but also the deeper, often overlooked causes, ranging from hormonal imbalances to gut health and emotional well-being.

Staying true to its ethos of elegance and restraint, PRIVÉ delivers refined, natural-looking results that focus on restoration, not transformation. Every treatment, whether a regenerative facial, laser therapy, injectables, or advanced anti-aging solution, is thoughtfully selected to enhance one’s features while preserving individuality. Signature offerings include HydraFacial MD, Glass Glow Facials, Skin Boosters like Hyaluronic Acid and Polynucleotides, laser resurfacing, Morpheus8, Baby Botox, PRP, and IV therapies. Blending the latest medical innovations with an aesthetic eye, PRIVÉ ensures that every procedure is grounded in intention, prioritizing subtle enhancements, long-term skin health, and the patient’s unique goals.

The launch of the new clinic is not just a milestone for the brand but a testament to a growing shift in how wellness is being perceived in India. With its compassionate, science-backed, and artistically guided approach, PRIVÉ Luxe is leading a new movement—one that embraces natural beauty, emotional healing, and personalized care. For those seeking authentic transformation and lasting results in a truly luxurious environment, PRIVÉ Luxe is more than a clinic—it is a sanctuary for self-renewal.

The post PRIVÉ LUXE Opens Its Second Clinic in Delhi Featuring Pioneering PDRN + Exosome Therapy appeared first on NRI News.